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Poly (ADP-ribose) polymerases, abbreviated as PARPs, are a group of familiar proteins that play a central role in DNA
repair employing the base excision repair (BER) pathway. There about 17 proteins in this family out of which the
primary nuclear PARPs are PARP-1, PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a and -5b) .The PARP family
members are known to engage in a wide range of cellular activities, for example, DNA repair, transcription, cellular
signaling, cell cycle regulation and mitosis amongst others. The chief functional units of PARP-1 are an amino
terminal DNA binding domain (DBD), a central auto modification domain (AMD), and a carboxyl-terminal catalytic
domain (CD). PARP inhibitors are currently undergoing clinical trials as targeted treatment modalities of breast,
uterine, colorectal and ovarian cancer. This review summarizes current insights into the mechanism of action of
PARP inhibitors, its recent clinical trials, and potential next steps in the evaluation of this promising class of
anti-cancer drugs.
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Poly (ADP-ribose) polymerases, abbreviated as PARPs,
are a group of familiar proteins that play a central role
in DNA repair employing the base excision repair (BER)
pathway. These nuclear proteins possess enzymatic and
scaffolding properties and govern the repair of single
strand breaks in DNA [1]. A true poly(ADP-ribose) poly-
merase (PARP) can transfer the first ADP-ribose moiety
from nicotinamide adenine dinucleotide (NAD+) to an
acceptor protein (preferably to glutamate or lysine resi-
dues) and can sequentially add multiple ADP-ribose
units to the preceding ones to form poly(ADP-ribose)
(pADPr) chains. There about 17 proteins in this family
out of which the primary nuclear PARPs are PARP-1,
PARP-2, PARP-3, and tankyrases 1 and 2 (PARP-5a
and -5b). The PARP family members are known to
engage in a wide range of cellular activities, for example,
DNA repair, transcription, cellular signaling, cell cycle
regulation and mitosis amongst others [2-6].
Environmental exposures and cell replication result in
DNA damage that is repaired by a variety of mechanisms,
including base excision repair (BER), mismatch repair
(MMR), nucleotide excision repair (NER), single strand
annealing (SSA), homologous recombination (HR), and* Correspondence: Coolaslam8@hotmail.com
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polymerases (PARPs) are a family of proteins involved in
DNA repair that utilize the BER pathway and share
enzymatic and scaffolding properties. PARP1 and PARP2
are the best studied members of this family of enzymes.
PARP1 has three domains that are responsible for DNA-
binding, automodification, and catalysis. DNA cleavage
results in the recruitment and binding of PARP1 to the
site of damage, with an increase in its catalytic activity,
and the formation of long, branched, poly (ADP-ribose)
(PAR) chains. PAR has a net negative charge that pro-
motes recruitment of DNA repair proteins involved in the
BER pathway to the site of DNA damage, and facilitates
removal of PARP1 from damage sites, allowing access to
other repair proteins. Apart from its role in BER, PARP1
has been implicated in the HR and NHEJ pathways, sug-
gesting a broader role for this enzyme family in the overall
DNA repair process. PARP1 and PARP2 are the ones
extensively studied and well known to be stimulated by
DNA damage [7-9]. The discovery of their existence was
made in 1963, and since then over 40 years of extensive
research efforts has brought forth the fruitful results of
their potential as therapeutic agents for cancer [8].
Characterized best amongst the PARP super family
members; PARP1 has an integrated structure based on
many independently folded domains out of which three
are the most important. The chief functional units ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(DBD), a central auto modification domain (AMD), and
a carboxyl-terminal catalytic domain (CD) [3,5]. PARP1
is over expressed in a variety of cancers. Its expression
has been linked with prognosis of cancers, most notably
breast cancer [10]. PARP1 and its product, PAR, can
respond to a variety of endogenous and exogenous stress
signals including those generated by oxidative, genotoxic,
thermal, oncogenic, metabolic and inflammatory stresses.
These responses trigger pathological conditions such as
cancer, inflammation related diseases, autoimmune dis-
eases, neurodegenerative diseases and metabolic stresses.
PARP inhibitors can therefore be followed upon as a the-
rapeutic solution to these pathologic states [11].
PARP inhibitors in clinical development imitate the
nicotinamide moiety of nicotinamide adenine dinucleo-
tide, and bind to the enzyme’s catalytic domain, inhibiting
auto modification and subsequent release of the enzyme
from the site of DNA damage. Simultaneously, they also
impede access of other repair proteins to the site of DNA
damage [9].
PARP inhibitors are currently undergoing clinical trials
as targeted treatment modalities for cancer. Environmen-
tal and genetic stressors that disrupt the cell cycle are vital
to the etiology and progression of cancer. Henceforth,
PARP-1 is an indispensible role player in tumour cell
development and PARP-1 targeted therapy can positively
predict the outcome in cancer therapy. Clinical trials have
been undertaken to assess the safety and efficacy profiles
of PARP inhibitors for management of breast, uterine,
colorectal and ovarian cancers [1].
The efficacy of these drugs may be due to the phe-
nomenon of synthetic lethality. This phenomenon
targets cells deficient in one DNA repair pathway by inhi-
biting another. Tumor cells in which the BRCA gene is
mutated are unable to repair DSBs by HRR and hence are
reliant on other DNA repair pathways, such as BER
pathway, which can preclude the development of double
stranded breaks DSBs in DNA. Inhibiting PARP activity
and subsequent BER pathway in such cells causes the
unrepaired single stranded breaks to develop into double
stranded breaks and leads to cell death. Such ‘synthetic
lethality’ carries implications for the development of anti-
cancer drugs [12]. Some tumors possess faulty Homolo-
gous Recombination (HR) mechanisms that arise from
acquired flaws in the HR pathway rather than germ
line BRCA mutations- this property being known as
BRCAness. It can occur as a consequence of epigen-
etic modifications of BRCA 1/2 and/or mutations in
various proteins crucial to HR pathways such as
RAD51, RAD54, DSS1, RPA1, ATM, CHK2 and PTEN
and has been related to several malignancies including
triple-negative breast cancer and sporadic serous ovarian
cancer [13-15].Inhibiting PARP activity uncovers potential of PARP
inhibitors as promising candidates for cancer therapy,
particularly in BRCA1/2 mutated cancers, alone or in
combination with cytotoxic drugs [12,16,17]. p53-deficient
breast cancer cells treated with a PARP Inhibitor happen
to lose resistance to an apoptosis promoting, clinically
active antitumor agent called doxorubicin [18]. As we
established previously, PARP inhibitors were recently
developed on the rationale of synthetic lethality, how-
ever this concept was well illustrated by Byrant et all
and Farmer et all in 2005. They demonstrated that,
breast cancer cells containing germ line mutations in
BRCA1 and BRCA 2 genes become sensitized to PARP
inhibitors in a PARP1 dependant manner and lose sensi-
tivity to PARP inhibition on regaining BRCA2 functional-
ity [19]. A clinical trial of a PARP inhibitor drug, Olaparib,
based on the approach of synthetic lethality, has given
successful results (minimal side effects with safely ad-
ministrable doses) in breast cancers containing BRCA1/2
mutations [16].
The first PARP inhibitor, Nicotinamide, was identified
in 1971. Second generation drugs were recognized sub-
sequently. Although agents having selective activity upon
PARP-1 and PARP-2 have been identified, most PARP
inhibitors are non-selective, affecting PARP-1 as well as
PARP-2 [1].
As of the present day, PARP inhibitors have been
explored either as sole agents in BRCA-1/2 depleted
cancer or in cancers possessing BRCA-ness, or combined
with other DNA damaging moieties such as ionizing ra-
diation in an expansive array of cancers. There are a
total of nine drugs in the hierarchy of phases of drug
development [20-22].
AZD2281 (Olaparib) is a small molecule oral PARP1/
2 and TNKS inhibitor with the commonly observed tox-
icities of nausea, vomiting, diarrhea and fatigue [16,23].
It is currently undergoing phase I and phase II clinical
trials as single agent or in combination therapy with
chemotherapy in different cancers like breast, ovarian
and colorectal cancers [24].
AG-014699 (PF-01367338) Rucaparib is an intraven-
ous PARP inhibitor with no significant toxicities when
used alone. It was examined in combination with temozo-
lomide in advanced solid tumors [25]. When this combin-
ation was used as a first line intervention in patients with
metastatic melanoma, bone marrow toxicity was observed
[26]. Currently it is being evaluated in Phase II trials as
solo agent in BRCA associated breast and ovarian cancers
and in Phase I trials in combination with chemotherapy
for advanced solid malignancies [24].
ABT-888 (Veliparib) is an oral PARP-1/2 inhibitor with
decent oral bioavailability and apparent CNS penetration
[20]. It is currently being explored in Phase I and II
Trials in combination with radiation and chemotherapy,
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cancer, colorectal cancer, glioblastoma multiforme and
melanoma [24].
MK-4827 (niraparib), an orally available compound,
demonstrating strong PARP-1 and PARP-2 inhibitory
activity has the side effects of nausea, vomiting, fatigue
and thrombocytopenia [27]. It is currently enrolled in
Phase I trials as a single agent or in combination regimens
with carboplatin in advance solid cell malignancies [24].
CEP-9722 is an oral PARP-1/2 inhibitor and a pro-
drug of CEP-8983. It has the capability of sensitizing
tumor cells in glioblastoma, colon cancer, neuroblastoma
and rhabdomyosarcoma to TMZ, irinotecan and radiation
without augmenting myelosuppression [28]. It is currently
under trial as single agent and in combination therapy
with Temoolomide in advanced solid malignancies [23].
E7016 (GPI-21016) (formerly known as GPI-21016) is
an orally bioavailable PARP inhibitor that can enhance
tumor radio sensitivity and also synergies with temozol-
mide and radiation to potentiate their effect [29]. It is also
enrolled in an ongoing Phase I trial which is exploring its
efficacy in combination with temozolomide in advanced
solid tumors and gliomas [23].
Other orally bioavailable potent PARP inhibitor agents
include INO-1001, MP-124 and LT-00673 which are also
undergoing Phase I clinical development trials [20].
Main function of radiotherapy is to produce DNA
strand breaks, causing severe DNA damage and leading
to cell death. Radiotherapy has the potential to kill 100%
of any targeted cells, but the dose required to do so
would cause unacceptable side effects to healthy tissue.
Radiotherapy therefore can only be given up to a certain
level of radiation exposure. Combining radiation therapy
with PARP inhibitors offers promise, since the inhibitors
would lead to formation of double strand breaks from
the single-strand breaks generated by the radiotherapy
in tumor tissue with BRCA1/BRCA2 mutations. This
combination could therefore lead to either more power-
ful therapy with the same radiation dose or similarly
powerful therapy with a lower radiation dose.
It is astonishing to know that the utility of PARP
inhibitors as therapeutic candidates is not limited to their
efficacy in treating malignancies. Over the decade, they
have emerged with a spectrum of actions that incorpo-
rates treating other conditions such as cardiovascular
diseases, stroke, metabolic disorders, diabetes, and auto-
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